Vimian’s Interim Report for the first quarter of 2022

Regulatory press release
May 24 2022

Vimian’s Interim Report for the first quarter of 2022

Strong growth and profitability in Q1

  • Revenue increased by 55 per cent to EUR 67.9m (43.7), of which 7.2 per cent was organic growth
  • Adjusted EBITA amounted to EUR 20.5m (17.7), corresponding to an adjusted EBITA margin of 30.2 per cent (40.5)
  • Operating profit amounted to EUR 11.2m (11.4), including items affecting comparability of EUR -4.7m (-3.6)
  • Earnings per share before and after dilution totaled EUR 0.01 (0.03)

“Vimian continues to deliver strong growth and profitability, despite a turbulent macroeconomic environment. Total revenue increased by 55 percent to EUR 67.9 million mainly driven by acquisitions. Organic growth was 7.2 percent, despite very tough comparatives. We delivered a healthy 30.2 per cent adjusted EBITA margin, higher than previous quarters with benefit from the annual order program in MedTech”, says Dr. Fredrik Ullman, CEO of Vimian Group.

Last twelve months pro-forma revenues (including all acquisitions completed between April 2021 to March 2022 as if they were consolidated from 1st April 2021) reached EUR 246.6 million and pro-forma EBITDA EUR 73.4 million.

“Since the start of the year, we welcomed eight new businesses to Vimian strengthening our position in the global veterinary market and adding new products and capabilities to the Group. Including these acquisitions, pro-forma revenues for the past twelve months reached EUR 246.6 million and EBITDA 73.4 million”, says Dr. Fredrik Ullman, CEO of Vimian Group.

A telephone and web conference will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
SE: +46 850558369
UK: +44 3333009035
US: +1 6467224903

To attend the webcast

Related presentation materials will be available at Vimian’s corporate website ( ahead of the telephone and web conference.